ANI Pharmaceuticals adds Henry Gosebruch to board, Shanmugam resigns directorship

ANI Pharmaceuticals, Inc. announced that its Board of Directors appointed Henry Gosebruch to serve as a director effective August 19, 2026, with a term expiring at the Company's 2027 annual meeting of stockholders.¹

Gosebruch, age 53, has served as Chief Executive Officer and a board member of Lakefront Biotherapeutics NV, formerly Galapagos NV, since May 2025.¹ Before that, he was President and Chief Executive Officer of Neumora Therapeutics, Inc., a publicly traded neuroscience company, from July 2023 to February 2025.¹ Prior to Neumora, he served as Executive Vice President and Chief Strategy Officer at AbbVie Inc. from December 2015 to February 2023, overseeing corporate strategy, competitive intelligence, business development, and M&A.¹ During his AbbVie tenure, his group completed more than 100 transactions and investments, including AbbVie's acquisition of Allergan.¹ Before AbbVie, he spent more than 20 years at J.P. Morgan, where he was Co-Head of the North American M&A Group.¹

The company disclosed no related-party ties tied to the appointment: there is no arrangement or understanding between Gosebruch and any other person under which he was selected as a director, and he is not party to any transactions requiring disclosure under Item 404(a) of Regulation S-K.¹ As compensation, Gosebruch will receive an initial restricted stock award with a grant date fair value of $525,000 upon joining the Board, vesting in three equal installments on the first, second, and third anniversaries of his joining.¹

Separately, Muthusamy "Samy" Shanmugam informed the Board on August 23, 2026 of his decision to resign as a director effective immediately, though he will remain ANI's Head of Research and Development and Chief Operating Officer of New Jersey Operations.¹